SFRP5 and metabolic dysfunction-associated steatotic liver disease: Among them, SFRP5 hepatic expression was recently reported to be associated with NAFLD in morbidly obese people [50], and the CpG methylation level of SFRP5 was inversely correlated with its expression in NAFLD patients [46].